RIPK3 and acute lymphoblastic leukemia: Moriwaki K et al. showed that treatment with the proteasome inhibitors MG132 and bortezomib can directly activate the necroptotic pathway in the ALL-derived cell line Jurkat, which is based on the RIPK3-MLKL interaction via RHIM domains [154].